48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort.
Cabello-Ubeda A, de Quirós JCLB, Martín Carbonero L, Sanz J, Vergas J, Mena Á, Torralba M, Hernández Segurado M, Pinto A, Tejerina F, Palmier E, Gutiérrez Á, Vázquez P, Pulido F, Górgolas M.
Cabello-Ubeda A, et al. Among authors: gorgolas m.
PLoS One. 2022 Nov 21;17(11):e0277606. doi: 10.1371/journal.pone.0277606. eCollection 2022.
PLoS One. 2022.
PMID: 36409695
Free PMC article.